NANO Nanobiotix SA

NANOBIOTIX ANNONCE LA PREMIERE INJECTION DE NBTXR3 A UN PATIENT ATTEINT D’UN CANCER DU PANCREAS AINSI QUE LES NOTIFICATIONS “SAFE TO PROCEED” DE LA FDA AMERICAINE POUR DEUX AUTRES ESSAIS CLINIQUES

NANOBIOTIX ANNONCE LA PREMIERE INJECTION DE NBTXR3 A UN PATIENT ATTEINT D’UN CANCER DU PANCREAS AINSI QUE LES NOTIFICATIONS “SAFE TO PROCEED” DE LA FDA AMERICAINE POUR DEUX AUTRES ESSAIS CLINIQUES
FR
13/10/2020

Underlying

NANONanobiotix SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nanobiotix SA

Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Thomas Zlowodzki
FP TOTAL SE
EQNR EQUINOR ASA
PROX PROXIMUS SA DE DROIT PUBLIC
GALP GALP ENERGIA SGPS SA CLASS B
BVI BUREAU VERITAS SA
SDG SYNERGIE SA
ITRK INTERTEK GROUP PLC
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
NANO NANOBIOTIX SA
REP REPSOL SA
ARG ARGAN SA
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ANR ANSWEAR.COM
AERO MONTANA AEROSPACE AG
SHEL SHELL PLC
SGSN SGS SA
04/02/26 April 2, 2026 1 EN
Ahmed Ben Salem ... (+2)
  • Ahmed Ben Salem
  • Thomas Zlowodzki
FP TOTAL SE
EQNR EQUINOR ASA
PROX PROXIMUS SA DE DROIT PUBLIC
GALP GALP ENERGIA SGPS SA CLASS B
BVI BUREAU VERITAS SA
SDG SYNERGIE SA
ITRK INTERTEK GROUP PLC
VETO VETOQUINOL SA
ENI ENI S.P.A.
MBB MBB INDUSTRIES SE
NANO NANOBIOTIX SA
REP REPSOL SA
ARG ARGAN SA
IDR INDRA SISTEMAS S.A. CLASS A
BP. BP P.L.C.
DMP DERMAPHARM HOLDING SE
ERF EUROFINS SCIENTIFIC SOCIETE EUROPEENNE
ANR ANSWEAR.COM
AERO MONTANA AEROSPACE AG
SHEL SHELL PLC
SGSN SGS SA
04/02/26 April 2, 2026 1 FR
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
04/02/26 April 2, 2026 1 EN
Khouloud Ben Aziza ... (+2)
  • Khouloud Ben Aziza
  • Martial Descoutures
04/02/26 April 2, 2026 1 FR
 PRESS RELEASE
Free
NANO NANOBIOTIX SA

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financi...

NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lung cancerClinical results reported across multiple tumor types including esophageal cancer, pancreatic cancer, melanoma, head and neck cancer, and lung cancer that supported the broad potential of JNJ-1900 (NBTXR3) across solid tumors treated with radiotherapy next to the completion of the transfer of spo...

March 31, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch